Showing 681-690 of 8076 results for "".
DermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addresSocial media marketing trends for 2022 and beyond
https://practicaldermatology.com/topics/practice-management/social-media-marketing-trends-for-2022-and-beyond/20095/Social media is no longer the new frontier in digital marketing. It is a vital part of daily life for much of your audience. That means it is an indispensable part of a good marketing strategy for your dermatology practice. This short video from Ekwa Marketing (www.ekwa.com) covers the latest trendsIs it time to consider telemedicine at your dermatology practice?
https://practicaldermatology.com/topics/practice-management/is-it-time-to-consider-telemedicine-at-your-dermatology-practice/19779/Telemedicine is in high demand, now more than ever. This Ekwa Marketing video explores how well it fits with dermatology practices, and what it takes to implement it.DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acTalking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Tips on Expanding Your Practice Focus to Men
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-on-expanding-your-practice-focus-to-men/18699/“I see the male patient as a huge opportunity I think men have been largely overlooked,” says Terrence Keaney, MD. He explains what procedures and services appeal to men, talks about the fundamentals of building a male-friendly practice, and offers tips to make male patients more comfortable undergoTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?Laser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.Overcoming Challenges in Topical Psoriasis Care
https://practicaldermatology.com/topics/psoriasis/overcoming-challenges-in-topical-psoriasis-care/18685/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for palmar plantar psoriasis and the combined use of topical corticosteroids with phototherapy. They also address alternative topical agents like topical immunomodulators.Allergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.